Archive for category: ASCO 2014

Thoughts on combination therapies

0 / May 31, 2014 9:27 am

orning it’s Day 1 of ASCO 2014 and it’s already a mad house. The combo Phase 1 study of ipilimumab, dabrafenib (BRAF inhib) and trametinib (MEK inhib) has been presented. Interestingly, the doublet combination (Ipi plus Dab) did not […]

ASCO 2014 Saturday Melanoma Preview

0 / May 30, 2014 10:22 pm

pmental Therapeutics AM session: Oral abstract: Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM). [This is interesting because […]

ASCO preview 2014: TheMelanomaCenter edition

0 / May 30, 2014 8:20 pm

17;s once again time for ASCO, or the American Society of Clinical Oncology, where more than 25,000 oncology doctors as well as countless pharma, biotech, genomic testing, and assorted media types converge on downtown Chicago and the McCormick Convention Center […]

Shopping Cart (0 Items)
Your cart is empty!

Subtotal: $0.00
Total: $0.00